company background image
301207 logo

Hualan Biological Vaccine SZSE:301207 Stock Report

Last Price

CN¥19.12

Market Cap

CN¥11.4b

7D

-2.8%

1Y

-39.3%

Updated

22 Nov, 2024

Data

Company Financials +

Hualan Biological Vaccine Inc.

SZSE:301207 Stock Report

Market Cap: CN¥11.4b

Hualan Biological Vaccine Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hualan Biological Vaccine
Historical stock prices
Current Share PriceCN¥19.12
52 Week HighCN¥32.56
52 Week LowCN¥15.42
Beta0.82
11 Month Change0.16%
3 Month Change22.33%
1 Year Change-39.30%
33 Year Changen/a
5 Year Changen/a
Change since IPO-59.20%

Recent News & Updates

Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Oct 08
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Recent updates

Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Oct 08
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Jul 25
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Jun 11
Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Apr 03
Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Apr 02
Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

Apr 01
Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

Mar 04
An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

Shareholder Returns

301207CN BiotechsCN Market
7D-2.8%-0.8%-0.9%
1Y-39.3%-17.3%5.4%

Return vs Industry: 301207 underperformed the CN Biotechs industry which returned -17.3% over the past year.

Return vs Market: 301207 underperformed the CN Market which returned 5.4% over the past year.

Price Volatility

Is 301207's price volatile compared to industry and market?
301207 volatility
301207 Average Weekly Movement10.7%
Biotechs Industry Average Movement8.8%
Market Average Movement8.3%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.6%

Stable Share Price: 301207's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 301207's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2005770Wenjue Anwww.hualanbacterin.com

Hualan Biological Vaccine Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China.

Hualan Biological Vaccine Inc. Fundamentals Summary

How do Hualan Biological Vaccine's earnings and revenue compare to its market cap?
301207 fundamental statistics
Market capCN¥11.38b
Earnings (TTM)CN¥497.61m
Revenue (TTM)CN¥1.65b

22.9x

P/E Ratio

6.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301207 income statement (TTM)
RevenueCN¥1.65b
Cost of RevenueCN¥364.32m
Gross ProfitCN¥1.29b
Other ExpensesCN¥787.59m
EarningsCN¥497.61m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.84
Gross Margin77.91%
Net Profit Margin30.17%
Debt/Equity Ratio4.9%

How did 301207 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

72%

Payout Ratio